Chewy, Inc. — Form 10-K Summary
Period clarification: The supplied filing is Chewy’s fiscal-year 2021 Form 10-K for the 52 weeks ended January 30, 2022, filed March 29, 2022. It is not a 2020 Q4 filing; the summary below reflects the filing provided.
Business context
Chewy operates a U.S. online pet-products and pet-healthcare business, selling through its website and mobile apps. It reported one operating and reportable segment. Its network included 14 fulfillment centers, and its offering included more than 100,000 products from over 3,000 brands. Autoship customer sales represented 70.2% of net sales.
Financial and operating results
| Metric | FY2021 | FY2020 | Change |
|---|---|---|---|
| Net sales | $8.891 billion | $7.146 billion | +24.4% |
| Gross profit / margin | $2.374 billion / 26.7% | $1.821 billion / 25.5% | Margin +1.2 percentage points |
| Operating loss | $(72.2) million | $(90.5) million | Loss narrowed |
| Net loss / net margin | $(73.8) million / (0.8)% | $(92.5) million / (1.3)% | Loss narrowed |
| Adjusted EBITDA / margin (non-GAAP) | $78.6 million / 0.9% | $85.2 million / 1.2% | EBITDA down 7.8% |
| Operating cash flow | $191.7 million | $132.8 million | +44.4% |
| Capital expenditures | $183.2 million | $130.7 million | Increased |
| Free cash flow (non-GAAP) | $8.6 million | $2.0 million | Increased |
Active customers grew 7.6% to 20.7 million, while net sales per active customer rose 15.6% to $430. Autoship customer sales increased 27.7% to $6.245 billion. Sales growth reflected customer-base expansion and higher spending per customer, including growth in consumables and healthcare.
At January 30, 2022, cash and cash equivalents were $603.1 million and total current assets were $1.324 billion, versus current liabilities of $1.645 billion. The amended asset-based revolving credit facility had $462.9 million of borrowing capacity and no outstanding borrowings. Operating lease liabilities totaled $434.4 million; disclosed lease commitments also included $234.6 million for leases not yet commenced. Total assets were $2.086 billion and total liabilities were $2.072 billion.
Changes versus FY2020
- Revenue growth slowed to 24.4% from 47.4% in FY2020.
- Gross margin improved by about 1.2 percentage points, which management attributed to sales mix and margin expansion across consumables, hardgoods, and healthcare, along with supply-chain efficiencies.
- Despite the narrower GAAP net loss, adjusted EBITDA and adjusted EBITDA margin declined. SG&A rose 30.7%, including higher fulfillment costs, wages, benefits, recruiting, facility costs, and IT investment.
- Operating cash flow rose, but capital expenditures also increased substantially; free cash flow remained positive but was a modest $8.6 million.
Outlook, risks, contingencies, and unusual items
- Outlook: No quantified revenue, earnings, or cash-flow guidance is provided in the supplied filing. Management expects continued investment in technology, automation, marketing, healthcare, and fulfillment capacity, and says it believes cash and available revolver capacity will fund working capital, capital expenditures, and contractual obligations for at least 12 months.
- Management commentary and risks: Management cited difficult fulfillment-center labor markets, supply-chain shortages and disruptions, and inflation as pressures affecting sales, margins, and recovery. COVID-19 effects and their duration remained uncertain. Other material risks include intense competition, customer-acquisition economics, supplier concentration, shipping costs, fulfillment execution, cybersecurity, regulation of pharmacy and telehealth, and consumer spending.
- Healthcare expansion: Chewy expanded Connect with a Vet and medication compounding, began rolling out Practice Hub for veterinarians, and intended to offer pet wellness plans and insurance beginning in 2022. These plans are forward-looking and subject to execution and regulatory risks.
- Contingency: IBM alleged infringement of patents relating to Chewy’s website and app and sought unspecified damages, potentially trebled, injunctive relief, and costs. One of five patents was eliminated from the case; the company denied infringement, planned to defend itself, and said the possible loss or range was not estimable. Management did not believe resolution of matters then pending would materially affect results, financial condition, or cash flows, but noted outcomes could not be predicted with certainty.
- Audit focus: The auditor identified vendor rebates as a critical audit matter because of the volume and terms of agreements and the judgment involved in recording earned and deferred rebates. The financial-statement and internal-control audit opinions were unqualified; management and the auditor reported effective internal control over financial reporting.
- Other notable items: Chewy donated approximately $43 million in products and supplies to shelters and rescues. Share-based compensation was $77.8 million, down from $121.3 million. A full valuation allowance was maintained against net deferred tax assets due to the company’s history of losses.
Important facts for investors to verify
- Confirm the intended reporting period: this filing covers FY2021, not 2020 Q4.
- Track whether gross-margin gains persist as labor, freight, inflation, and supply-chain pressures evolve, and whether adjusted EBITDA margin recovers.
- Assess cash generation after capital expenditures and working-capital movements; FY2021 free cash flow was only $8.6 million.
- Review current-liability coverage, lease commitments, planned fulfillment investments, and actual availability under the borrowing-base facility.
- Monitor the IBM litigation and pharmacy/telehealth regulatory matters, including any updated loss estimates or outcomes.
- Evaluate the assumptions behind customer growth, $430 sales per active customer, Autoship penetration, and the planned insurance and veterinary-platform expansion.
Adjusted EBITDA and free cash flow are non-GAAP measures; the company cautions that they should be considered alongside GAAP results and cash-flow measures.